Simcere Pharmaceutical Group Limited (02096.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	15.8B	7.7B	6.6B	6.6B	6.3B
Cost of Revenue	2.8B	1.4B	1.3B	1.6B	1.3B
Gross Profit	12.9B	6.3B	5.3B	5.0B	5.0B
Operating Expenses
R&D Expense	2.4B	1.6B	1.4B	1.6B	1.7B
SG&A Expense	7.2B	3.5B	3.0B	2.8B	2.8B
General & Admin Expense	894.5M	599.3M	526.0M	487.8M	444.2M
Selling & Marketing Expense	4.3B	2.9B	2.5B	2.4B	2.4B
Other Expenses	511.1M	(319.5M)	36.2M	(135.0M)	(438.8M)
Total Operating Expenses	10.1B	4.8B	4.5B	4.3B	4.1B
Cost and Expenses	12.9B	6.2B	5.8B	5.9B	5.5B
Operating Income (EBIT)	2.9B	1.6B	848.0M	711.8M	862.5M
Non-Operating
Interest Income	119.9M	55.8M	39.2M	55.0M	59.9M
Interest Expense	149.3M	95.8M	69.6M	34.6M	34.4M
Net Interest Income	(72.8M)	(40.1M)	(30.3M)	20.4M	25.5M
Other Non-Op Income/Expense	(61.4M)	(41.2M)	(28.2M)	28.2M	25.6M
Non-Operating Income (excl Interest)	(58.8M)	138.4M	(287.7M)	(62.8M)	254.3M
EBT (Pre-Tax Income)	2.8B	1.5B	819.9M	740.0M	888.2M
Income Tax Expense	357.2M	170.3M	86.7M	26.1M	(40.5M)
Bottom Line
Net Income	2.4B	1.3B	733.2M	714.8M	930.9M
Earnings from Cont. Ops	2.4B	1.3B	733.2M	714.0M	926.7M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	2.4B	1.3B	733.2M	714.8M	930.9M
Per Share
Basic EPS	HK$0.96	HK$0.54	HK$0.29	HK$0.27	HK$0.36
Diluted EPS	HK$0.96	HK$0.54	HK$0.29	HK$0.27	HK$0.36
Revenue Per Share	HK$6.18	HK$3.11	HK$2.63	HK$2.53	HK$2.42
Shares
Basic Shares Outstanding	2.6B	2.5B	2.5B	2.6B	2.6B
Diluted Shares Outstanding	2.6B	2.5B	2.5B	2.6B	2.6B
Profitability Metrics
EBITDA	3.5B	1.7B	1.4B	1.1B	815.4M
D&A	621.9M	302.0M	214.3M	309.6M	209.0M
EBIT	2.9B	1.4B	1.1B	774.6M	606.3M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026